Erdafitinib 与 Vinflunine 或 Docetaxel 或 Pembrolizumab 在患有晚期尿路上皮癌和选定的成纤维细胞生长因子受体 (FGFR) 基因畸变的参与者中进行比较的研究 (THOR)
Erdafitinib 与 Vinflunine 或 Docetaxel 或 Pembrolizumab 在患有晚期尿路上皮癌和特定 FGFR 基因畸变的受试者中进行比较的 3 期研究
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
A study of erdafitinib versus standard of care, consisting of chemotherapy (docetaxel or vinflunine) or anti-PD-(L) 1 agent pembrolizumab, in participants with advanced urothelial cancer and selected FGFR aberrations who have progressed on or after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2). It will consist of screening, treatment phase (from randomization until disease progression, intolerable toxicity, withdrawal of consent or decision by investigator to discontinue treatment, post-treatment follow-up (from end-of-treatment to participants death, withdraws consent, lost to follow-up study completion for the respective cohort, whichever comes first). The study will have long term extension (LTE) period after clinical cutoff date is achieved for final analysis of each cohort and participants eligible in the opinion of the investigator, will continue to benefit from the study intervention. Efficacy, pharmacokinetics, biomarkers, patient reported outcomes, medical resource utilization and safety will be assessed.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 第三阶段
扩展访问
扩展访问
得到正式认可的
- 可用:此研究性治疗目前可扩展访问,未参与临床研究的患者可能能够访问药物、生物制品或医疗设备正在研究中。
- 不再可用:此干预措施以前可扩展访问权限,但目前不可用,将来也不可用。
- 暂时不可用:该干预措施目前不提供扩展访问权限,但预计将来会提供。
- 批准上市:该干预措施已获得美国食品和药物管理局批准供公众使用。
联系人和位置
学习地点
-
-
-
Beijing、中国、100730
- Beijing Hospital
-
Beijing、中国、100730
- Peking Union Medical College Hospital
-
Beijing、中国、100191
- Peking University Third Hospital
-
Beijing、中国、100050
- Beijing Friendship Hospital
-
Beijing、中国、100034
- Peking University First Hospital
-
Beijing、中国、100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Changchun、中国、130021
- The First Bethune Hospital of Jilin University
-
Chengdu、中国、610041
- Sichuan University Huaxi Hospital
-
Chengdu、中国、610000
- Sichuan Provincial Peoples Hospital
-
Chongqing、中国、400030
- Chongqing University Cancer Hospital
-
Guangzhou、中国、510180
- Guangzhou First Municipal People's Hospital
-
Guangzhou、中国、510120
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Guangzhou、中国、510060
- Sun Yat Sen University Cancer Center
-
Hangzhou、中国、310014
- Zhejiang Provincial People's Hospital
-
Hangzhou、中国、310020
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanchang、中国、330006
- The First Affliated Hospital Of Nanchang University
-
Nanjing、中国、210009
- Jiangsu Cancer Hospital
-
Nanjing、中国、210008
- Nanjing Drum Tower Hospital
-
Shanghai、中国、200127
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai、中国、200400
- Huadong Hospital Affiliated to Fudan University
-
Shenyang、中国、110004
- Shengjing Hospital Of China Medical University
-
Shenzhen、中国、518055
- Shenzhen university General Hospital
-
Wenzhou、中国、325000
- First Affiliated Hospital Of Wenzhou Medical College
-
Xi'an、中国、710061
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Dnipro、乌克兰、49102
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
-
Dnipro、乌克兰、49100
- Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council
-
Dnipropetrovsk、乌克兰、49005
- MI Dnipropetrovsk Region Clinical Hospital n a I.I.Mechnikov
-
Ivano-Frankivsk、乌克兰、76008
- Ivano-Frankivsk Regional Clinical Hospital
-
Kharkiv、乌克兰、61070
- Municipal non-profit enterprise 'Regional Center of Oncology'
-
Kharkiv、乌克兰、61037
- Regional Medical Clinical Center for Urology and Nephrology named after V.I. Shapoval
-
Kyiv、乌克兰、03022
- National Cancer Institute
-
Kyiv、乌克兰、03115
- State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center
-
Lviv、乌克兰、79010
- Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'
-
Uzhhorod、乌克兰、88000
- Transkarpathian Regional University Oncology Clinic
-
Vinnitsa、乌克兰、21029
- Podilskiy Regional Center of Oncology
-
Zaporizhzhya、乌克兰、69040
- Zaokod
-
Zaporizhzhya、乌克兰、69600
- Zaporizhzhia medical Academy of postgraduate education, Zaporizhzhia Regoinal Clinical Hospital
-
-
-
-
-
Haifa、以色列、31096
- Rambam Health Care Campus
-
Jerusalem、以色列、91120
- Hadassah Medical Center
-
Kfar Saba、以色列、44281
- Meir Medical Center
-
Petach Tikvah、以色列、49100
- Rabin Medical Center, Beilinson Hospital
-
Tel Aviv、以色列、64239
- Sourasky Medical Center
-
Tel HaShomer、以色列、52621
- The Chaim Sheba Medical Center
-
Tzrifin、以色列、70300
- Assaf Harofeh Medical Center
-
-
-
-
-
Barnaul、俄罗斯、656049
- Altai Regional Oncology Dispensary
-
Chelyabinsk、俄罗斯、454087
- Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine
-
Irkutsk、俄罗斯、664035
- Irkutsk Regional Oncology Dispensary
-
Ivanovo、俄罗斯、153040
- Ivanovo Regional Oncology Dispensary
-
Kostroma、俄罗斯、156005
- Kostroma regional oncology dispensary
-
Kuzmolovsky、俄罗斯、188663
- Leningrad Regional Oncology Dispensary
-
Moscow、俄罗斯、105077
- City Clinical Hospital n.a. D.D.Pletnev
-
Moscow、俄罗斯、117997
- Russian Scientific Center of Roentgenoradiology
-
Moscow、俄罗斯、119991
- I.M. Sechenov First Moscow State Medical University
-
Moscow、俄罗斯、125284
- Hertzen Oncology Research Institute
-
Moscow、俄罗斯、115478
- FSBSI 'N. N. Blokhin Russian Cancer Research Center'
-
Nal'chik、俄罗斯、360017
- City Clinical Hospital #1
-
Nizhny Novgorod、俄罗斯、603109
- Privolzhsky District Medical Center under the Federal Medico-Biological Agency
-
Omsk、俄罗斯、644013
- Clinical Oncology Dispensary
-
Pyatigorsk、俄罗斯、357502
- GBUZ of Stavropol region Pyatigorsk Oncological Dispensary
-
Saint Petersburg、俄罗斯、196603
- Private Medical Institution Euromedservice
-
Saint Petersburg、俄罗斯、197758
- Russian Scientific Center of Radiology and Surgical Technologies
-
Saint Petersburg、俄罗斯、192148
- LLC 'Strategic Medical Systems'
-
Saint Petersburg、俄罗斯、195067
- Clinical hopital n/a Petra velikogo
-
Saint Petersburg、俄罗斯、197022
- Pavlov First Saint Petersburg State Medical University
-
Saint Petersburg、俄罗斯、197758
- Saint-Petersburg Clinical Scientific And Practical Center For Special Types Of Medical Care
-
Saransk、俄罗斯、430032
- FGBOU Vo Mordovian National Research State University N. A. N.P. Ogareva
-
Saratov、俄罗斯、410000
- Saratov State Medical University
-
Smolensk、俄罗斯、214031
- LLC Uromed
-
Sochi、俄罗斯、354057
- GBUZ Oncology Centre #2 of Healthcare Department of Krasno
-
Tyumen、俄罗斯、625041
- Multifunctional clinical medical center 'Medical city'
-
Ufa、俄罗斯、450000
- Bashkiria State Medical University
-
Vologda、俄罗斯、160012
- Vologda Regional Oncological Dispensary
-
-
-
-
-
Pleven、保加利亚、5800
- UMHAT 'Dr. Georgi Stranski', EAD
-
Plovdiv、保加利亚、4004
- Complex Oncology Center - Plovdiv EOOD
-
Sofia、保加利亚、1407
- Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'
-
Sofia、保加利亚、1797
- UMHAT Sofia Med
-
Varna、保加利亚、9010
- Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD
-
-
-
-
British Columbia
-
Kelowna、British Columbia、加拿大、V1Y 5L3
- BC Cancer Agency - Southern Interior
-
Vancouver、British Columbia、加拿大、V5Z 4E6
- Vancouver Cancer Centre
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3E 0V9
- Cancercare Manitoba
-
-
Ontario
-
Thunder Bay、Ontario、加拿大、P7B 6V4
- Thunder Bay Regional Health Sciences Centre
-
Toronto、Ontario、加拿大、M5G 2M9
- Princess Margaret Hospital- UHN
-
-
Saskatchewan
-
Regina、Saskatchewan、加拿大、S4T 7T1
- Saskatchewan Cancer Agency (SCA) - Allan Blair Cancer Centre
-
-
-
-
-
Budapest、匈牙利、1082
- Semmelweis Egyetem
-
Budapest、匈牙利、1122
- Országos Onkológiai Intézet, Urogenitális Tumorok és Klinikai Farmakológiai Osztály
-
Budapest、匈牙利、H-1145
- Budapesti Uzsoki Utcai Korhaz
-
Nyíregyháza、匈牙利、04400
- Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
-
Pécs、匈牙利、7624
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
-
-
-
-
Kaohsiung City、台湾、807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Niao-Sung Hsiang、台湾、833
- Chang Gung Medical Foundation
-
Taichung、台湾、40447
- China Medical University Hospital
-
Taichung、台湾、40705
- Taichung Veterans General Hospital
-
Tainan、台湾、70403
- National Cheng Kung University Hospital
-
Tainan、台湾、710
- Chi Mei Medical Center Yong Kang
-
Taipei、台湾、10002
- National Taiwan University Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
Taipei、台湾、10449
- Mackay Memorial Hospital
-
Taipei、台湾、11259
- Koo Foundation Sun Yat-Sen Cancer Center
-
Taoyuan、台湾、333
- Chang-Gung Memorial Hospital, LinKou Branch
-
-
-
-
-
Adana、土耳其(türkiye)、01120
- Baskent University Adana Practice and Research Center Kisla Health Campus
-
Ankara、土耳其(türkiye)、6100
- Hacettepe University Medical Faculty
-
Istanbul、土耳其(türkiye)、34098
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Istanbul、土耳其(türkiye)、34147
- Bakirkoy Training and Research Hospital
-
Istanbul、土耳其(türkiye)、34722
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul、土耳其(türkiye)、34214
- Medipol Mega University Hospital
-
Istanbul、土耳其(türkiye)、34093
- Bezmialem University Medical Faculty
-
Istanbul、土耳其(türkiye)、34890
- Pendik Training and Research Hospital
-
Izmir、土耳其(türkiye)、35340
- Dokuz Eylul Universitesi Tip Fakultesi
-
Izmir、土耳其(türkiye)、35100
- Ege University
-
Kocaeli、土耳其(türkiye)
- Kocaeli University Medical Faculty
-
Malatya、土耳其(türkiye)、44400
- Inonu Universitesi Turgut Ozal Tip Merkezi, Ic Hastaliklari
-
-
-
-
-
Aguascalientes、墨西哥、20230
- Medicos Especialistas en Cancer, S.C.
-
Chihuahua City、墨西哥、31000
- Centro Estatal de Cancerología de Chihuahua
-
Naucalpan、墨西哥、53100
- Oncologia Integral Satelite
-
-
-
-
-
Graz、奥地利、8036
- LKH-Univ. Klinikum Graz
-
Linz、奥地利、4020
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg、奥地利、5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna、奥地利、1020
- Krankenhaus der Barmherzigen Brüder
-
Vienna、奥地利、A-1090
- Medical University Vienna MUV
-
-
-
-
-
Barretos、巴西、14784-400
- Fundacao Pio XII
-
Belo Horizonte、巴西、30130-100
- Universidade Federal De Minas Gerais - Hospital das Clínicas
-
Belo Horizonte、巴西、30380-472
- Nucleo de Ensino e Pesquisa do Instituto Mario Penna
-
Curitiba、巴西、80530-010
- Instituto de Oncologia do Parana
-
Curitiba、巴西、81520 060
- Liga Paranaense de Combate ao Cancer
-
Goiânia、巴西、74605-070
- Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
-
Itajaí、巴西、88301-220
- Clínica de Neoplasias Litoral Ltda.
-
Jaú、巴西、17210 080
- Fundacao Doutor Amaral Carvalho
-
Natal、巴西、59075-740
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre、巴西、90035-903
- Hospital das Clinicas de Porto Alegre
-
Porto Alegre、巴西、91350 200
- Hospital Nossa Senhora da Conceicao S A
-
Rio de Janeiro、巴西、22250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro、巴西、20231 050
- Ministerio da Saude Instituto Nacional do Cancer
-
Salvador、巴西、41253-190
- Hospital Sao Rafael
-
Santo André、巴西、09060-650
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
Sorocaba、巴西、18030-005
- Instituto de Oncologia de Sorocaba Onco Clinicas Especializadas
-
São José do Rio Preto、巴西、15090-000
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
-
São Paulo、巴西、04502-001
- Instituto D Or de Pesquisa e Ensino IDOR
-
São Paulo、巴西、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、巴西、05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo、巴西、03102-002
- Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia
-
São Paulo、巴西、01308 050
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes 1
-
-
-
-
-
Athens、希腊、15125
- Athens Medical Center
-
Athens、希腊、11526
- Errikos Dunant Hospital Center
-
Athens、希腊、15562
- Metropolitan General A E
-
Athens、希腊、115 28
- University of Athens Medical School - Regional General Hospi
-
Larissa、希腊、41110
- University Hospital Of Larissa
-
Pátrai、希腊、26504
- University General Hospital of Rio Patras
-
Thessaloniki、希腊、54645
- Euromedica General Clinic
-
Thessaloniki、希腊、14564
- Interbalkan European Medical Center
-
Thessaloniki、希腊、56403
- Papageorgiou General Hospital Of Thessaloniki
-
-
-
-
-
Berlin、德国、10967
- Vivantes Klinikum Am Urban
-
Braunschweig、德国、38126
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Dresden、德国、01307
- Universitatsklinikum Carl Gustav Carcus Dresden
-
Düsseldorf、德国、40225
- Universitaetsklinikum Duesseldorf
-
Erlangen、德国、91054
- Friedrich-Alexander Universitaet Urologische Universitaetskl
-
Frankfurt、德国、60590
- Universitatsklinikum Frankfurt
-
Freiburg im Breisgau、德国、79106
- Universitatsklinikum Freiburg
-
Greifswald、德国、17475
- Universitätsmedizin Greifswald
-
Göttingen、德国、37099
- Universitatsmedizin Gottingen
-
Hamburg、德国、22763
- Asklepios Klinik Altona
-
Hanover、德国、30625
- Medizinische Hochschule Hannover
-
Lübeck、德国、23538
- Universitatsklinikum Schleswig Holstein Campus Lubeck
-
Mannheim、德国、68167
- Medizinische Fakultät Mannheim der Universität Heidelberg
-
Münster、德国、48149
- Universitaetsklinikum Muenster
-
Nürtingen、德国、72622
- Studienpraxis Urologie Drs. Feyerabend
-
Regensburg、德国、93053
- Caritas-Krankenhaus St. Josef
-
Rostock、德国、18057
- Universitaetsmedizin Rostock
-
Velbert、德国、42551
- MVZ-Onkologie Velbert GbR
-
Weiden、德国、92637
- Kliniken Nordoberpfalz AG/Klinikum Weiden
-
-
-
-
-
Alessandria、意大利、15121
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo Alessandria
-
Arezzo、意大利、52100
- Ospedale S. Donato - Asl 8 Arezzo
-
Aviano、意大利、33081
- CRO IRCCS Istituto Nazionale Tumori
-
Bergamo、意大利、24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Brescia、意大利、25123
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
-
Cremona、意大利、26100
- Istituti Ospitalieri di Cremona, AO di Cremona
-
Florence、意大利、50139
- Oncologia Medica
-
Genova、意大利
- SPDC Villa Scassi
-
Meldola、意大利、47014
- IRST Meldola Forli
-
Milan、意大利、20132
- IRCCS Ospedale San Raffaele
-
Milan、意大利、20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan、意大利、20141
- European Institute of Oncology
-
Modena、意大利、41124
- AOU Policlinico di Modena
-
Naples、意大利、80131
- IRCCS-Fondazione Pascale
-
Novara、意大利、28100
- Ospedale Maggiore della Carita
-
Orbassano、意大利、10043
- Aou San Luigi Gonzaga
-
Padova、意大利、35128
- Istituto Oncologico Veneto Iov Irccs Padova
-
Parma、意大利、43126
- AOU di Parma
-
Pavia、意大利、27100
- IRCCS Policlinico San Matteo
-
Pavia、意大利、27100
- Ist. Clinici Scientifici Maugeri - Unità Operativa di Oncolo
-
Pisa、意大利、56126
- Azienda Ospedaliero Universitaria Pisana
-
Poggibonsi (SI)、意大利、53100
- Usl 7 Siena - Ospedale Alta Valdelsa ASL TOSCANA SUD-EST
-
Province of Macerata、意大利、62100
- UOC Oncologia Ospedale Provinciale di Macerata
-
Roma、意大利、00168
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Siena、意大利、53100
- Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
-
Torino、意大利、10123
- Oncologia Medica-Città Della Salute E Della Scienza Di Torino
-
Torrette Di Ancona、意大利、60126
- Azienda Ospedaliero - Universitaria Ospedali Riuniti
-
-
-
-
-
Chiba、日本、260-8717
- Chiba Cancer Center
-
Hirosaki、日本、036-8563
- Hirosaki University Hospital
-
Kashiwa、日本、277 8577
- National Cancer Center Hospital East
-
Kita Gun、日本、761 0793
- Kagawa University Hospital
-
Kobe、日本、650-0047
- Kobe City Medical Center General Hospital
-
Koshigaya、日本、343-8555
- Dokkyo Medical University Saitama Medical Center
-
Matsuyama、日本、791-0280
- Aso Co.,Ltd Iizuka Hospital
-
Miyazaki、日本、889-1692
- University of Miyazaki Hospital
-
Nagano、日本、381-8551
- Nagano Municipal Hospital
-
Nagoya、日本、464 8681
- Aichi Cancer Center Hospital
-
Osaka、日本、545 8586
- Osaka City University Hospital
-
Osaka、日本、541 8567
- Osaka International Cancer Institute
-
Sagamihara、日本、252-0375
- Kitasato University Hospital
-
Sakura、日本、285-8741
- Toho University Sakura Medical Center
-
Sapporo、日本、003-0804
- National Hospital Organization Hokkaido Cancer Center
-
Shinjuku-ku、日本、162-8666
- Tokyo Women's Medical University Hospital
-
Tokyo、日本、105-8470
- Toranomon Hospital
-
Tokyo、日本、135 8550
- The Cancer Institute Hospital of JFCR 1
-
Tsukuba、日本、305 8576
- University of Tsukuba Hospital
-
Ube、日本、755-8505
- Yamaguchi University Hospital
-
Yokohama、日本、232 0024
- Yokohama City University Medical Center
-
Ōsaka-sayama、日本、589-8511
- Kindai University Hospital
-
Ōta-ku、日本、373-8550
- Gunma Prefectural Cancer Center
-
-
-
-
-
Aalst、比利时、9300
- OLV Ziekenhuis Aalst
-
Antwerp、比利时、2020
- ZNA Middelheim
-
Brussels、比利时、1200
- Cliniques Universitaires Saint Luc
-
Charleroi、比利时、6000
- Clinique Notre Dame de Grâce
-
Ghent、比利时、9000
- AZ Maria Middelares
-
Ghent、比利时、9000
- UZ Gent
-
Liège、比利时、4000
- CHC MontLegia
-
Wilrijk、比利时、2610
- Sint-Augustinus AZ
-
Yvoir、比利时、5530
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Angers、法国、49055
- Institut de Cancerologie de l Ouest ICO
-
Besançon、法国、25030
- Hopital Jean Minjoz
-
Bordeaux、法国、33000
- Institut Bergonie
-
Brest、法国、29609
- CHRU Brest - Hopital Morvan
-
Clermont-Ferrand、法国、63011
- Centre Jean Perrin
-
Dijon、法国、21079
- Centre Georges-François Leclerc
-
Lille、法国、59000
- Centre Oscar Lambret
-
Lille、法国、59000
- Hôpital Privé Le Bois
-
Lorient、法国、56322
- Groupe Hospitalier Bretagne Sud
-
Marseille、法国、13005
- Hopital de la Timone
-
Montpellier、法国、34298
- Institut Regional du Cancer de Montpellier Val d'Aurelle
-
Nice、法国、06189
- Centre Antoine Lacassagne
-
Nîmes、法国、30029
- Institut de Cancérologie du Gard
-
Paris、法国、75475
- Hospital Saint-Louis
-
Paris、法国、75015
- Hopital Europeen Georges-Pompidou
-
Pierre-Bénite、法国、69495
- Hospices Civils de Lyon HCL
-
Poitiers、法国、86021
- CHU De Poitiers
-
Rennes、法国、35062
- Centre Eugene Marquis
-
Ris-Orangis、法国、91130
- Centre de radiothérapie et d'Oncologie médicale de l'Essonne
-
Saint-Priest-en-Jarez、法国、42271
- Institut de Cancérologie de Loire
-
Strasbourg、法国、67098
- Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
-
Toulouse、法国、31059
- Institut Claudius Regaud
-
Valenciennes、法国、59300
- Centre Les Dentellieres
-
Villejuif、法国、94805
- Institut Gustave Roussy
-
-
-
-
-
Bydgoszcz、波兰、85 796
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Warsaw、波兰、02-507
- Centralny Szpital Kliniczny MSWiA w Warszawie
-
Warsaw、波兰、02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wroclaw、波兰、50 556
- Uniwersytecki Szpital Kliniczny we Wroclawiu
-
-
-
-
-
Camperdown、澳大利亚、2050
- Chris O'Brien Lifehouse
-
Frankston、澳大利亚、3199
- Peninsula & South Eastern Haematology and Oncology Group
-
Kogarah、澳大利亚、2217
- St George Hospital
-
Melbourne、澳大利亚、3000
- Peter MacCallum Cancer Centre
-
Melbourne、澳大利亚、3199
- Frankston Hospital
-
Murdoch、澳大利亚、6150
- Fiona Stanley Hospital
-
-
-
-
Alaska
-
Anchorage、Alaska、美国、99503
- Alaska Urological Institute dba Alaska Clinical Research Center
-
-
California
-
Sacramento、California、美国、95817
- University of Calif Davis Medical Center
-
St. Helena、California、美国、94574
- St. Helena Hospital - Martin-O'Neil Cancer Center
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Miami、Florida、美国、33136
- University of Miami Sylvester Cancer Center
-
Orange、Florida、美国、32763
- Mid Florida Hematology Oncology
-
-
Georgia
-
Atlanta、Georgia、美国、30318-0922
- Piedmont Cancer Institute
-
-
Illinois
-
Chicago、Illinois、美国、60612
- Rush University
-
Hines、Illinois、美国、60141
- Edward Hines Jr V A Hospital
-
-
Kentucky
-
Louisville、Kentucky、美国、40207
- Norton Cancer Institute
-
-
Maryland
-
Lanham、Maryland、美国、20706
- Maryland Oncology Hematology, PA
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109-5000
- University of Michigan Health System
-
-
Nevada
-
Reno、Nevada、美国、89509
- VA Sierra Nevada Health Care System
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New York、New York、美国、10029
- Weill Cornell Medical College
-
The Bronx、New York、美国、10461
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- Levine Cancer Institute, Carolinas HealthCare System
-
Salisbury、North Carolina、美国、28144
- W G Bill Hefner VA Medical Center
-
-
Ohio
-
Cincinnati、Ohio、美国、45242
- Oncology Hematology Care
-
-
Texas
-
Fort Worth、Texas、美国、76104
- The Center for Cancer and Blood Disorders
-
Houston、Texas、美国、77030
- MD Anderson Cancer Center
-
Houston、Texas、美国、77024
- Texas Oncology-Memorial City
-
Tyler、Texas、美国、75702
- Texas Oncology Tyler
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- INOVA Dwiight &Martha Schar Cancer Institute
-
Norfolk、Virginia、美国、23502
- Virginia Oncology Associates
-
-
Washington
-
Seattle、Washington、美国、98108
- VA Puget Sound Healthcare System
-
-
-
-
-
Bristol、英国、BS2 8ED
- University Hospitals Bristol - Bristol Haematology & Oncolog
-
London、英国、W1G 6AD
- Sarah Cannon Research Institute
-
London、英国、W6 8RF
- Charing Cross Hospital
-
London、英国、EC1A 7BE
- St Bartholomew's Hospital
-
Manchester、英国、M20 4BX
- The Christie NHS Foundation Trust Christie Hospital
-
Plymouth、英国、PL6 8QH
- Derriford Hospital-Department of Medical Oncology
-
Sheffield、英国、S10 2 RX
- University of Sheffield
-
Southampton、英国、SO16 6YD
- Southampton General Hospital
-
Sutton、英国、SM2 5NG
- Royal Marsden Hospital
-
-
-
-
-
Amsterdam、荷兰、1066 CX
- Antoni van Leeuwenhoek
-
Nieuwegein、荷兰、3430 EM
- St. Antonius Ziekenhuis Nieuwegein
-
The Hague、荷兰、2545 CH
- Haga ziekenhuis
-
-
-
-
-
Lisbon、葡萄牙、1400-038
- Champalimaud Foundation Champalimaud Centre
-
Lisbon、葡萄牙、G1R 2J6
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon、葡萄牙、1500-458
- Hospital Lusíadas
-
Lisbon、葡萄牙、1649-035
- H. Santa Maria - Centro Hospitalar de Lisboa Norte
-
Porto、葡萄牙、4200072
- Instituto Portugues de Oncologia
-
-
-
-
-
Badajoz、西班牙、06006
- Hosp. Univ. Infanta Cristina
-
Badalona、西班牙、08916
- Institut Català D'Oncologia-Hospital Universitari Germans Trias I Pujol
-
Barcelona、西班牙、08041
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona、西班牙、08036
- Hosp Clinic de Barcelona
-
Cáceres、西班牙、10003
- Hosp. San Pedro de Alcantara
-
Córdoba、西班牙、14004
- Hosp Reina Sofia
-
Granada、西班牙、18014
- Hosp. Univ. Virgen de Las Nieves
-
Jaén、西班牙、23007
- Complejo Hospitalario de Jaen
-
Las Palmas de Gran Canaria、西班牙、35016
- Hosp. Univ. Insular de Gran Canaria
-
Lugo、西班牙、27003
- Hosp. Univ. Lucus Augusti
-
Madrid、西班牙、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、西班牙、28046
- Hosp. Univ. La Paz
-
Majadahonda、西班牙、28220
- Hosp. Univ. Pta. de Hierro Majadahonda
-
Manresa、西班牙、08243
- ALTHAIA, Xarxa Assistencial Universitària de Manresa
-
Pamplona、西班牙、31008
- Hosp. de Navarra
-
Seville、西班牙、41013
- Hosp. Virgen Del Rocio
-
Seville、西班牙、41009
- Hosp. Virgen Macarena
-
Valencia、西班牙、46014
- Hosp. Gral. Univ. Valencia
-
Valencia、西班牙、46026
- Hosp. Univ. I Politecni La Fe
-
Zaragoza、西班牙、50009
- Hosp. Univ. Miguel Servet
-
-
-
-
-
Buenos Aires、阿根廷、C1426AGE
- Centro Oncológico Korben
-
Buenos Aires、阿根廷、C1419AHN
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
Buenos Aires、阿根廷、C1431FWN
- CEMIC Saavedra
-
Córdoba、阿根廷、X5000KPH
- Centro Urologico Profesor Bengio
-
Córdoba、阿根廷、C5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Mar del Plata、阿根廷、B7602CBM
- Hospital Privado de Comunidad
-
Pergamino、阿根廷、B2700CPM
- Centro de Investigacion Pergamino SA
-
Viedma、阿根廷、R8500ACE
- Clínica Viedma
-
-
-
-
-
Busan、韩国、49241
- Pusan National University Hospital
-
Daejeon、韩国、35015
- Chungnam National University Hospital
-
Goyang-si、韩国、410-769
- National Cancer Center
-
Gwangju、韩国、61469
- Chonnam National University Hospital
-
Gyeonggi-do、韩国、13620
- Seoul National University Bundang Hospital
-
Incheon、韩国、21565
- Gachon University Gil Medical Center
-
Seoul、韩国、03080
- Seoul National University Hospital
-
Seoul、韩国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韩国、03181
- Kangbuk Samsung Hospital
-
Seoul、韩国、02841
- Korea University Anam Hospital
-
Seoul、韩国、135-710
- Samsung Medical Center
-
Wŏnju、韩国、26426
- Yonsei University Wonju Severance Christian Hospital
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components ( less than [<] 50 percent [%] overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
- Metastatic or surgically unresectable urothelial cancer
- Documented progression of disease, defined as any progression that requires a change in treatment, prior to randomization
- Cohort 1: Prior treatment with an anti-PD-(L) 1 agent as monotherapy or as combination therapy; no more than 2 prior lines of systemic treatment. Cohort 2: No prior treatment with an anti-PD-(L) 1 agent; only 1 line of prior systemic treatment. Subjects who received neoadjuvant or adjuvant chemotherapy and showed disease progression within 12 months of the last dose are considered to have received systemic therapy in the metastatic setting.
- A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum)
- Participants must meet appropriate molecular eligibility criteria
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- Adequate bone marrow, liver, and renal function
Exclusion Criteria:
- Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomization
- Active malignancies (that is, requiring treatment change in the last 24 months). The only allowed exceptions are: urothelial cancer, skin cancer treated within the last 24 months that is considered completely cured, localized prostate cancer with a gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localized prostate cancer with a gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
- Symptomatic central nervous system metastases
- Received prior fibroblast growth factor receptor (FGFR) inhibitor treatment
- Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
- Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade.
- History of uncontrolled cardiovascular disease
- Impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Cohort 1 (Arm 1A): Erdafitinib
Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision. |
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
其他名称:
FGFRi CTA will be used to determine molecular eligibility. |
|
实验性的:Cohort 1 (Arm 1B): Vinflunine or Docetaxel
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system. |
FGFRi CTA will be used to determine molecular eligibility. Participants will receive vinflunine 320 mg/m^2 as a 20-minute intravenous infusion. Participants will receive docetaxel 75 mg/m^2 as a 1 hour intravenous infusion. |
|
实验性的:Cohort 2 (Arm 2A): Erdafitinib
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision. |
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
其他名称:
FGFRi CTA will be used to determine molecular eligibility. |
|
实验性的:Cohort 2 (Arm 2B): Pembrolizumab
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first. |
FGFRi CTA will be used to determine molecular eligibility. Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
|
Overall survival was measured from the date of randomization to the date of the participant's death. |
From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
大体时间:From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)
|
PFS was defined as the time from the date of randomization to the date of disease progression or relapse from complete response (CR) based on investigator assessment using RECIST v 1.1, or death due to any cause, whichever occurred first. As per RECIST v 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). Progressive disease (PD) was defined as at least 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of greater than or equal to (>=) 5 mm or appearance of at least 1 new lesion. |
From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)
|
|
Objective Response Rate (ORR) Per RECIST Version 1.1
大体时间:From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months
|
ORR was defined as the percentage of participants who achieved CR or partial response (PR) as determined by investigator per RECIST v1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months
|
|
Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl)
大体时间:Baseline up to Cycle 11 (each cycle was of 21 days)
|
The FACT-Bl consisted of 39 items, with 5-point Likert scales, covering 5 primary domains: physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns for participants with bladder cancer. The response options ranged from 0 to 4 where, 0='Not at all" and 4= "very much." FACT-Bl total score ranged from 0 (worst) to 156 (best). The higher the score, the better the quality of life (QOL). The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Time Until Symptom Deterioration
大体时间:Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months
|
Time until symptom deterioration was defined as the first time to increase in urinary bladder cancer symptoms score from the day of randomization beyond a meaningful change threshold compared to baseline. The urinary bladder cancer symptom score was subset of FACT-Bl which included 3 items related to urinary symptoms, 5-point Likert scale. Response options ranged from 0 to 4, 0 = Not at all, 1= A little bit, 2= Somewhat, 3=Quite a bit, 4 = Very much. A response of 0 indicated no symptoms and 4 indicated severe symptoms. Total sum scores ranged from 0 to 12, higher scores indicate relatively poor quality of life. |
Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months
|
|
Percentage of Participants With Shift From Baseline in Patient-Global Impression of Severity (PGIS)
大体时间:Baseline, 51.7 months
|
The PGI-S was a single item patient-reported measure assessing participants' impression of severity in bladder cancer symptoms. It uses a 4-point Likert scale as follows: symptoms are: 0-"absent (no symptoms)", 1-"mild", 2-"moderate", 3="severe" and 4= "very severe". Percentage of participants with shift from baseline in PGIS score were reported. A negative shift from baseline in PGIS score indicated Improvement and positive shift from baseline in PGIS score indicated Worsening. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline, 51.7 months
|
|
Change From Baseline in Utility Scale of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
大体时间:Baseline up to Cycle 11 (each cycle was of 21 days)
|
The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ visual analog scale (VAS) recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Change From Baseline in Visual Analog Scale (VAS) of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
大体时间:Baseline up to Cycle 11 (each cycle was of 21 days)
|
The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ VAS recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Duration of Response (DOR) as Per RECIST Version 1.1
大体时间:From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)
|
DOR was defined as time from the date of initial documentation of an overall response (CR or PR) to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experience CR) or death. As per RECIST Version 1.1: CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of >=5 mm or appearance of at least 1 new lesion. |
From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
大体时间:From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were the events between first dose of study drug and up to 30 days after last dose or before start of new anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure. |
From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)
|
|
Number of Participants With Shift From Baseline Grade Less Than or Equal to (<=) 2 to Grade Greater Than or Equal to (>=) 3 Post-Baseline in Laboratory Parameter: Hematology
大体时间:From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
Hematology parameters included: hemoglobin, platelet count, white blood cell (WBC) count, and absolute neutrophil count (ANC). According to national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE) version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of hematology parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure. |
From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Shift From Baseline Grade <= 2 to Grade >=3 Post-Baseline in Laboratory Parameter: Chemistry
大体时间:From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
Chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, bicarbonate, corrected calcium, magnesium, potassium, sodium, serum phosphate, serum parathyroid hormone. According to NCI-CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of chemistry parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure. |
From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Abnormalities in Electrocardiograms (ECG) Parameters
大体时间:Day 1 of Cycle 2 and 4 (Each Cycle 21 days)
|
Number of participants with abnormalities in ECG parameters were reported. The ECG variables included heart rate, RR interval, PR interval, QRS interval, QT interval and QT corrected according to Fridericia's formula (QTcF). ECG abnormality criteria include: Heart rate: Low <50 beats per minute (bpm); High > 100 bpm, RR interval: Low < 600 milliseconds (ms); High > 1000 ms, QT interval: High > 500 ms, QTc interval: High > (450 ms for males, 470 ms for females); increase to >500 ms. |
Day 1 of Cycle 2 and 4 (Each Cycle 21 days)
|
|
Change From Baseline in Vital Signs: Weight
大体时间:Baseline, 51.7 months
|
Changes from baseline in vital signs (weight) was reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. |
Baseline, 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Amsler Grid Test
大体时间:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in Amsler grid test was reported. Baseline and post-baseline visit findings included normal, abnormal CS (clinically significant) and abnormal NCS (not clinically significant). Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Visual Acuity
大体时间:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in visual acuity (VA) was reported. Worst post-baseline was defined as the visual acuity value that resulted in the largest change from baseline value for either eye. Baseline value was considered for the eye that reported the worst-post baseline value. Baseline and post-baseline visit visual acuity findings included: <= 20/30, >20/30 to <= 20/40, >20/40 to <= 20/80, >20/80 to <= 20/120, >20/120 to <= 20/160, >20/160 to <= 20/200, >20/200. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening in visual acuity from baseline value to worst post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Subretinal Fluid
大体时间:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for subretinal fluid was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only category (shift from absent at baseline to increased at post-baseline) in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Retinal Pigment Epithelium (RPE) Elevation
大体时间:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for RPE elevation was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Slit Lamp Biomicroscopy: Retinal Assessment
大体时间:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in slit lamp biomicroscopy examination for retinal assessment was reported. Baseline and post-baseline visit findings included normal, abnormal CS and abnormal NCS. Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Oral Clearance (CL/F) of Erdafitinib
大体时间:Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)
|
Clearance was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. |
Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) of Erdafitinib
大体时间:Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)
|
Area under the plasma concentration time-curve from time zero to the time t (AUC[0-t]) was reported. |
Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)
|
合作者和调查者
调查人员
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- CR108401
- 2017-002932-18 (EudraCT编号)
- 42756493BLC3001 (其他标识符:Janssen Research & Development, LLC)
- 2017 (美国 NIH 拨款/合同)
- 2023-510296-56-00 (注册表标识符:EUCT number)
- 2023 (美国 NIH 拨款/合同)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.